Immunotherapy

Lung cancer immunotherapy is rapidly evolving beyond traditional checkpoint inhibitors to overcome resistance and treat more patients. New approaches focus on directly engaging immune cells and targeting multiple tumor pathways, improving effectiveness in both small cell and non-small cell lung cancer. A major breakthrough is tarlatamab, the first BiTE approved for a solid tumor, which […]

ELI-002 2P is an innovative “off-the-shelf” therapeutic vaccine targeting KRAS mutations, which drive approximately 90% of pancreatic cancers and 50% of colorectal cancers . Unlike personalized mRNA vaccines, this standardized approach delivers synthesized peptides directly to lymph nodes to train T-cells to recognize and attack KRAS-mutated cancer cells. Key Clinical Results: The Phase 1 AMPLIFY-201 trial

Zongertinib is a newly approved oral targeted therapy for patients with unresectable or metastatic HER2-mutated non-squamous non-small cell lung cancer (NSCLC) who have received prior treatment. Approved by the FDA in August 2025, it is the first oral option specifically for this patient group, marking a significant advance in targeted lung cancer therapy. Zongertinib works